Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. The company is ranked fourth on the list of largest biomedical companies by revenue.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| MRK | Merck & Co., Inc. | 2026-03-03 12:09:25 | 120.52 | -0.89 | -0.73 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MRK | 0000310158 | Merck & Co., Inc. | US58933Y1055 | — | 221918501 | NYSE | 2834 | Pharmaceutical Preparations | 1231 | NJ | 126 EAST LINCOLN AVENUE | RAHWAY | NJ | 07065 | UNITED STATES | US | 908-740-4000 | 126 EAST LINCOLN AVENUE, RAHWAY, NJ, 07065 | 126 EAST LINCOLN AVENUE, RAHWAY, NJ, 07065 | Merck & Co. Inc. | Pharmaceuticals | 1891 | Robert M. Davis | 75,000 | http://merck.com | 198,051,000,000 | 3,577,103,522 | 2,472,392,003 | Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. The company is ranked fourth on the list of largest biomedical companies by revenue. | 2026-02-26 15:06:14 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 198,051,000,000 | -115,748,000,000 | -36.886 | 2,472,392,003 | -53,644,237 | -2.1237 |
| 2024 | 313,799,000,000 | 20,870,000,000 | 7.1246 | 2,526,036,240 | -6,607,632 | -0.2609 |
| 2023 | 292,929,000,000 | 62,109,000,000 | 26.908 | 2,532,643,872 | -5,948,595 | -0.2343 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Richard R. Deluca, Jr. | President, Executive Vice President | 2024 | 958,747 | 0 | 5,699,835 | 1,096,680 | 114,511 | 9,098,531 |
| Betty Larson | Chief Human Resources Officer, Executive Vice President | 2024 | 604,396 | 725,000 | 6,635,712 | 685,246 | 280,323 | 11,257,796 |
| Robert M. Davis | Chairman, President | 2024 | 1,623,874 | 0 | 13,077,541 | 2,761,650 | 561,112 | 23,186,064 |
| Caroline Litchfield | Chief Financial Officer, Executive Vice President | 2024 | 1,166,044 | 0 | 3,585,716 | 1,333,800 | 147,210 | 7,507,778 |
| Dean Li | President, Executive Vice President | 2024 | 1,451,077 | 0 | 4,724,760 | 1,659,840 | 170,183 | 10,086,332 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 75,000 |
| 2024 | 75,000 |
| 2023 | 72,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 65,011,000,000 | 64,168,000,000 | 60,115,000,000 |
| Cost Of Revenue | 16,382,000,000 | 15,193,000,000 | 16,126,000,000 |
| Gross Profit | — | — | — |
| Research And Development Expenses | 15,789,000,000 | 17,938,000,000 | 30,531,000,000 |
| General And Administrative Expenses | 10,733,000,000 | 10,816,000,000 | 10,504,000,000 |
| Operating Expenses | — | — | — |
| Operating Income | — | — | — |
| Net Income | 18,254,000,000 | 17,117,000,000 | 365,000,000 |
| Earnings Per Share Basic | 7.3 | 6.76 | 0.14 |
| Earnings Per Share Diluted | 7.28 | 6.74 | 0.14 |
| Weighted Average Shares Outstanding Basic | 2,502,000,000 | 2,532,000,000 | 2,537,000,000 |
| Weighted Average Shares Outstanding Diluted | 2,507,000,000 | 2,541,000,000 | 2,547,000,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 14,565,000,000 | 13,242,000,000 | 6,841,000,000 |
| Marketable Securities Current | 0 | 447,000,000 | 252,000,000 |
| Accounts Receivable | 1,600,000,000 | 2,100,000,000 | 3,000,000,000 |
| Inventories | 6,658,000,000 | 6,109,000,000 | 6,358,000,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 10,518,000,000 | 8,706,000,000 | 8,368,000,000 |
| Total Assets Current | 43,516,000,000 | 38,782,000,000 | 32,168,000,000 |
| Marketable Securities Non Current | 956,000,000 | 463,000,000 | 252,000,000 |
| Property Plant And Equipment | 25,316,000,000 | 23,779,000,000 | 23,051,000,000 |
| Other Assets Non Current | 18,818,000,000 | 16,044,000,000 | 11,996,000,000 |
| Total Assets Non Current | 125,000,000 | 78,324,000,000 | 74,507,000,000 |
| Total Assets | 136,866,000,000 | 117,106,000,000 | 106,675,000,000 |
| Accounts Payable | 4,404,000,000 | 4,079,000,000 | 3,922,000,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | 2,589,000,000 | 2,649,000,000 | 1,372,000,000 |
| Other Liabilities Current | 14,468,000,000 | 15,694,000,000 | 15,766,000,000 |
| Total Liabilities Current | 28,327,000,000 | 28,420,000,000 | 25,694,000,000 |
| Long Term Debt | 46,750,000,000 | 34,462,000,000 | 33,683,000,000 |
| Other Liabilities Non Current | 7,688,000,000 | 6,465,000,000 | 8,792,000,000 |
| Total Liabilities Non Current | — | 0 | 600,000,000 |
| Total Liabilities | — | 100,000,000 | 250,000,000 |
| Common Stock | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 |
| Retained Earnings | 73,075,000,000 | 63,069,000,000 | 53,895,000,000 |
| Accumulated Other Comprehensive Income | -4,287,000,000 | -4,945,000,000 | -5,161,000,000 |
| Total Shareholders Equity | 52,606,000,000 | 46,313,000,000 | 37,581,000,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 2,793,000,000 | 2,395,000,000 | 2,044,000,000 |
| Share Based Compensation Expense | 820,000,000 | 761,000,000 | 645,000,000 |
| Other Non Cash Income Expense | -511,000,000 | -510,000,000 | -355,000,000 |
| Change In Accounts Receivable | 1,090,000,000 | 244,000,000 | 1,148,000,000 |
| Change In Inventories | 1,180,000,000 | 835,000,000 | 816,000,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 110,000,000 | 182,000,000 | -380,000,000 |
| Change In Other Liabilities | 195,000,000 | -49,000,000 | 456,000,000 |
| Cash From Operating Activities | 16,472,000,000 | 21,468,000,000 | 13,006,000,000 |
| Purchases Of Marketable Securities | 1,207,000,000 | 519,000,000 | 955,000,000 |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 4,112,000,000 | 3,372,000,000 | 3,863,000,000 |
| Acquisition Of Business | 10,042,000,000 | 746,000,000 | 0 |
| Other Investing Activities | 58,000,000 | 127,000,000 | 36,000,000 |
| Cash From Investing Activities | -13,741,000,000 | -7,734,000,000 | 0 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | 8,248,000,000 | 7,943,000,000 | 7,551,000,000 |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | 5,084,000,000 | 1,306,000,000 | 1,346,000,000 |
| Issuance Of Long Term Debt | — | — | 5,939,000,000 |
| Repayment Of Long Term Debt | 2,503,000,000 | 1,290,000,000 | 1,755,000,000 |
| Other Financing Activities | -131,000,000 | -372,000,000 | -328,000,000 |
| Cash From Financing Activities | -1,922,000,000 | -7,032,000,000 | -4,810,000,000 |
| Change In Cash | 1,372,000,000 | 6,409,000,000 | -5,864,000,000 |
| Cash At End Of Period | 14,565,000,000 | 13,242,000,000 | 6,841,000,000 |
| Income Taxes Paid | 6,086,000,000 | 3,928,000,000 | 4,338,000,000 |
| Interest Paid | 1,300,000,000 | 1,300,000,000 | 1,100,000,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | 7.3 | 6.76 | 0.14 |
| Price To Earnings Ratio | 14.4192 | 14.716 | 778.7143 |
| Earnings Growth Rate | 7.9882 | 4,728.5714 | -97.5567 |
| Price Earnings To Growth Ratio | 1.8051 | 0.0031 | -7.9822 |
| Book Value Per Share | 43.3809 | 46.2109 | 41.9492 |
| Price To Book Ratio | 2.4264 | 2.1527 | 2.5989 |
| Ebitda | 28,490,000,000 | 24,711,000,000 | 7,893,000,000 |
| Enterprise Value | 298,134,520,000 | 275,752,360,000 | 304,797,740,000 |
| Dividend Yield | 0.0313 | 0.0315 | 0.0273 |
| Dividend Payout Ratio | 0.4518 | 0.464 | 20.6877 |
| Debt To Equity Ratio | 0.9379 | 0.8013 | 0.9328 |
| Capital Expenditures | 4,330,000,000 | 3,123,000,000 | 3,673,000,000 |
| Free Cash Flow | 12,142,000,000 | 18,345,000,000 | 9,333,000,000 |
| Return On Equity | 0.347 | 0.3696 | 0.0097 |
| One Year Beta | 0.3824 | 0.2207 | 0.2542 |
| Three Year Beta | 0.3102 | 0.2603 | 0.2723 |
| Five Year Beta | 0.2922 | 0.4822 | 0.5147 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Guindo Chirfi | Chief Marketing Officer | 2026-02-12 | 10,000 | D | 60,615 |
| Li Dean Y | Executive VP & President, MRL | 2026-02-10 | 10,235 | D | 92,035 |
| Zachary Jennifer | EVP, General Counsel | 2026-02-09 | 25,946 | A | 94,861 |
| Zachary Jennifer | EVP, General Counsel | 2026-02-09 | 25,946 | D | 68,915 |
| Zachary Jennifer | EVP, General Counsel | 2026-02-09 | 56,792 | A | 125,707 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Thomas H Tuberville | Senator | 2023-11-16 | Sale (Full) | 2023-10-16 | Joint | $1,001 - $15,000 |
| John P Ricketts | Senator | 2023-10-20 | Sale (Full) | 2023-09-21 | Spouse | $50,001 - $100,000 |
| Thomas H Tuberville | Senator | 2022-04-08 | Purchase | 2022-03-30 | Joint | $1,001 - $15,000 |
| Thomas H Tuberville | Senator | 2021-07-23 | Sale (Full) | 2021-03-29 | Joint | $1,001 - $15,000 |
| David A Perdue , Jr | Senator | 2021-05-02 | Sale (Full) | 2020-04-14 | Joint | $15,001 - $50,000 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Julie Johnson | 2026-01-15 | TX32 | Sale | 2025-12-18 | Joint | $1,001 - $15,000 |
| Gilbert Cisneros | 2026-01-12 | CA31 | Purchase | 2025-12-19 | — | $1,001 - $15,000 |
| Gilbert Cisneros | 2025-12-15 | CA31 | Purchase | 2025-11-18 | — | $1,001 - $15,000 |
| Julie Johnson | 2025-12-11 | TX32 | Sale (Partial) | 2025-11-13 | Joint | $1,001 - $15,000 |
| Valerie Hoyle | 2025-10-10 | OR04 | Sale | 2025-09-23 | Spouse | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| TOBAM | 2025-12-31 | 1,940,000 | 18,429 | 105.2689 |
| Kensington Investment Counsel, LLC | 2025-12-31 | 4,036,300 | 38,346 | 105.26 |
| CAHILL FINANCIAL ADVISORS INC | 2025-12-31 | 503,161 | 4,780 | 105.2638 |
| Stokes Family Office, LLC | 2025-12-31 | 725,848 | 6,896 | 105.2564 |
| ONE WEALTH CAPITAL MANAGEMENT, LLC | 2025-12-31 | 251,782 | 2,392 | 105.26 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| PIMCO Equity Series | 2025-12-31 | PIMCO RAFI Dynamic Multi-Factor U.S. Equity ETF | MFUS | 23,440 | 2,467,294.4 | 1.1725 |
| RYDEX SERIES FUNDS | 2025-12-31 | Class H | RYNHX | 8,832 | 929,656.32 | 0.3579 |
| RYDEX SERIES FUNDS | 2025-12-31 | Class C | RYNCX | 8,832 | 929,656.32 | 0.3579 |
| RYDEX SERIES FUNDS | 2025-12-31 | Class A | RYANX | 8,832 | 929,656.32 | 0.3579 |
| RYDEX SERIES FUNDS | 2025-12-31 | Investor Class | RYNVX | 8,832 | 929,656.32 | 0.3579 |